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Abstract
Background: The vast majority of human genes (.70%) are alternatively spliced. Although alternative pre-mRNA
processing is modified in multiple tumors, alternative hyper-splicing signatures specific to particular tumor types are still
lacking. Here, we report the use of Affymetrix Human Exon Arrays to spot hyper-splicing events characteristic of myasthenia
gravis (MG)-thymoma, thymic tumors which develop in patients with MG and discriminate them from colon cancer changes.
Methodology/Principal Findings: We combined GO term to parent threshold-based and threshold-independent ad-hoc
functional statistics with in-depth analysis of key modified transcripts to highlight various exon-specific changes. These
denote alternative splicing in MG-thymoma tumors compared to healthy human thymus and to in-house and Affymetrix
datasets from colon cancer and healthy tissues. By using both global and specific, term-to-parent Gene Ontology (GO)
statistical comparisons, our functional integrative ad-hoc method allowed the detection of disease-relevant splicing events.
Conclusions/Significance: Hyper-spliced transcripts spanned several categories, including the tumorogenic ERBB4 tyrosine
kinase receptor and the connective tissue growth factor CTGF, as well as the immune function-related histocompatability
gene HLA-DRB1 and interleukin (IL)19, two muscle-specific collagens and one myosin heavy chain gene; intriguingly, a
putative new exon was discovered in the MG-involved acetylcholinesterase ACHE gene. Corresponding changes in
spliceosome composition were indicated by co-decreases in the splicing factors ASF/SF2 and SC35. Parallel tumor-associated
changes occurred in colon cancer as well, but the majority of the apparent hyper-splicing events were particular to MG-
thymoma and could be validated by Fluorescent In-Situ Hybridization (FISH), Reverse Transcription–Polymerase Chain
Reaction (RT-PCR) and mass spectrometry (MS) followed by peptide sequencing. Our findings demonstrate a particular
alternative hyper-splicing signature for transcripts over-expressed in MG-thymoma, supporting the hypothesis that
alternative hyper-splicing contributes to shaping the biological functions of these and other specialized tumors and
opening new venues for the development of diagnosis and treatment approaches.
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Introduction
Changes in gene expression, and particularly in alternative
splicing patterns are often disease-associated [1], and aberrant
alternative splicing (hyper-splicing) is one of the characteristics of
cancer cells [2], as well as of inflammation and autoimmune
muscle diseases[3]. The vast majority of human genes (.70%) are
alternatively spliced [4,5], and 75% of alternative splicing events
affect coding regions, yielding subtle amino acid substitutions,
removal of protein motifs or protein truncations [6]. This can alter
protein structures, yield cell-specific protein patterns [7] and
enlarge protein versatility in a tissue-specific manner [6].
However, tumor specific signatures of alternative hyper-splicing
are still lacking, primarily since alternative splicing studies are
based on expressed sequence tags (EST) or mRNA sequences
[8,9]. Poor coverage of low abundance transcripts [4], and
uncovered tissues, disease states and developmental stages [10]
hence call for the development of methodologies for identifying
alternative hyper-splicing signatures in specific tumor types.
In search for tumor-specific alternative hyper-splicing signa-
tures, we selected MG-thymoma, an epithelial tumor of the
thymus gland [11] where lymphoid precursor cells differentiate
into mature T-lymphocytes [12]. About one in three of all
thymoma patients develop Myasthenia Gravis (MG), a neuromus-
cular autoimmune disease characterized by abnormal neuromus-
cular transmission [13,14]. In MG, auto-immune antibodies
against the muscle nicotinic acetylcholine receptor are accompa-
nied by thymocytes hyperplasia. MG involves loss of acetylcholine
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receptors that initiate muscle contraction, which results in
progressive muscle weakness. Overall, more than 60% of MG
patients present a pathological thymus, including thymic hyper-
plasia in about 50% of patients and thymoma in 10 to 20% [14].
Understanding the role of alternative hyper-splicing of tumor-
related, muscle-specific and immune function genes in the etiology
of MG-thymoma can provide better diagnosis for patients and
offer more hope for their treatments [15].
Linkage between regulated genes and the corresponding
transcript quantities highlights tumor over-expressed transcripts
as preferred targets for identifying hyper-splicing signatures [16].
We have recently used UniGene microarrays [17] to identify such
over-expressed transcripts. However, those microarrays primarily
detect the 39-end of studied transcripts, disregarding transcript
levels. Thus, Agilent [18] 60-mer probes are located between 150
to 1100 bps from the target transcript 39-ends [18], whereas the 11
25-mer probes per gene of Affymetrix GC U133 Plus Arrays are
located in a 600 bp range from these genes 39-end [19]. Some of
these limitations were overcome in the high-density lithography-
based Affymetrix exon arrays [10,20], where each transcript is
interrogated by a large number of 25-mer probes [10] (50 in
average), located according to its complete RefSeq annotation,
and amplified RNA is prepared to cover the entire length of the
analyzed transcripts. The massive increase in probes (,5.6
million), along with exon length-dependent probe numbers,
enable unprecedented resolution into these genomic units. This
ensures more robust detection of gene-level transcription changes
[10] and allows the discovery of potentially new transcripts and
novel, predicted exons.
At the functional level, alternative hyper-splicing can modify
tumor properties, since gene products may play roles in multiple,
often seemingly unrelated, routes. To approach these processes,
tools for functional analyses of microarray data have been
developed [21]. These primarily involved post-hoc functional
analyses such as T-test, ANOVA [22] or clustering analyses [23]
(i.e first finding lists of changed genes, by various computational
methods, and then conducting functional enrichment analysis on
these lists, e.g. EASE [24] and MAPPFinder [25]). However,
translating a list of differentially expressed genes using annotation
databases suffers from several limitations. Primarily, this approach
overlooks transcripts that are involved in several biological
processes. In addition, most downstream analysis tools for gene
lists enable analyses of only one ontology abstraction level [21]. To
address these difficulties, methods that allow ad-hoc detection of
changed functional GO categories have been evolving. These
largely use threshold-based statistical approaches (i.e. binomial,
hypergeometric, chi-square or Fisher’s exact test) that detect
relative enrichments of gene categories given a population of genes
[21]. However, they involve high incidence of false negatives that
result from a unified, often arbitrary threshold [26,27].
To increase the range of solutions and enable detection of subtle
and non-trivial changes, several threshold-free methods were
developed (for example, GSEA [28] and a program based on
semantic similarities among GO terms [29]). These are based on
the Kolmogorov-Smirnov (KS) goodness-of-fit test [27,28,30,31],
which prevents neglecting most of the collected data but may be
more error-prone to false positives. Although rank-based methods
have been suggested [32,33], the important conceptual advantage
of threshold-freedom lies in considering gene expression data
simultaneously, without the uncertainty associated with prior gene
list extraction [26]. Combining both discrete and continuous data
analyses to detect changed functional gene GO categories from
expression data can thus provide several advantages for analyzing
microarrays [27].
We applied an ad-hoc method for multileveled testing of GO
categories enrichment in exon array-derived data sets by
combining a KS and Fisher Exact (Hypergeometric), with detailed
term-to-parent statistical analysis on the GO categories represent-
ed on the arrays. First, we analyzed our in-house MG-thymoma
study and the Affymetrix colon cancer [10] exon microarray data
set, which identified tumor-specific alternative splicing events
relevant to both tumors or specific to one of them. In-depth
analyses of exon-specific alterations involved several key tran-
scripts from the tumor-related, immune function and muscle-
characteristic GO categories and the MG-related ACHE gene,
which is ubiquitously expressed, undergoes alternative splicing at
both termini (39 and 59) and contributes to many different
biological processes [34].
To study the contribution of alternative splicing to tumor
biology, we developed a novel approach for identifying alternative
hyper-splicing signatures. Using human exon microarrays, we
compared MG-thymoma tumors from patients with MG to
Affymetrix datasets from healthy tissues and colon cancer.
Combined ad-hoc and post-hoc statistics with in-depth analysis of
key transcripts and FISH, RT-PCR and mass spectrometry
followed by peptide sequencing validation revealed pronounced
alternative hyper-splicing in several gene categories modified in
MG-thymoma tumors. These spanned tumorogenic, immune
function and muscle-specific transcripts, involved reduced expres-
sion of the splicing factors ASF/SF2 and SC35 and extended into
the discovery of a putative new exon in the MG-involved ACHE
gene. Together, these findings support the notion of a major
contribution of alternative hyper-splicing to MG-thymoma
features, opening new venues for diagnosis and treatment of
specific tumor types, and revealed specific tumor-type alternative
splicing signatures reflecting MG-thymoma and colon cancer
properties.
Results
To identify tumor-specific changes in gene expression, we used
in-house data of cortical thymoma tumors from MG patients and
normal thymuses and the Affymetrix sample data set [20] of colon
cancer versus normal colon and other healthy tissues. We applied
an integrative functional ad-hoc analysis method to gene-level
summary signals (median core probe sets or PLIER signal
estimates [10,20]). Each term was compared to the global array
population and to all its direct parent GO terms as well as to the
root of the tree: Molecular Function (MF) or Biological Process
(BP) (Figure 1). Additional statistical tests of location involved the
Kruskal-Wallis and variance tests. Within the categories that
changed specifically compared to their parent GO terms we
searched for genes containing core probe sets that changed by
more than 4-fold between MG-thymoma to control thymuses.
Iter-PLIER gene-level data of Affymetrix colon cancer data set
[20] (data will be given upon request) served for comparison of the
detected genes. In addition, we tested the sensitivity and specificity
of our ad-hoc approach by conducting it on the colon cancer data
set (results under Table S1) and found a wide overlap of tumor to
normal tissue data compared to other colon cancer 39 microarray
analyses and one proteomic data set. This revealed a higher level
of accuracy, superior to others’ published data sets in both post-
and ad-hoc approaches [20,24,35–37] (Text S1). We detected
100% of the categories identified by all the other methods, at the
significance levels of 0.05 and 0.001. Our total findings overlapped
with others ranged at 31–90%, with the closest (90.91%) achieved
by comparison to post-hoc analysis we applied on the Affymetrix
colon cancer exon array data set [20,24,35–37], making false
Tumor Specific Exon Signatures
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negatives unlikely. Importantly, 56.63% of the categories detected
by us at significance level of 0.01 were also detected by one or
more of the compared methods (Text S1), which exhibited lower
overlap ratios among them (26.74–43.97%). One functional
bioinformatics post-hoc method was similar to ours in detection
ratios compared to the other methods (56.76%) [35].
Global continuous and discrete term analyses reveal MG-
thymoma affected GO terms
To search for the molecular changes that underlie MG-
thymoma we applied our ad-hoc functional analysis and compared
each GO term to the global array population. We observed ample
changes in both BP and MF categories (Figure S1). Noticeably,
more categories decreased according to both approaches;
compatible with the exon and gene level changes, also when
compared to the colon cancer data set (Text S2, Figure S2) and
with the decrease in GO categories in hyperplasic thymuses [38].
Permutations of both MG-thymoma and colon cancer data sets
verified those global expression change difference (Figure S3). In
both MG-thymoma and colon cancer data sets, we found
differences between expression changes in the 39 compared to 59
at the whole genome level (Text S2, Figure S4–5). Noticeably,
MG-thymomas showed increase in muscle contraction (P,0.05 by
both discrete and continuous methods, Table S2) both in this and
in our previous study [38]. Totally, 85 BP and 97 MF categories
exhibited a change in MG-thymomas compared to healthy
thymuses. Predictably, more categories were detected by the
continuous approach as compared with discrete analyses (Text
S2). Nevertheless, decreased MF categories showed an almost total
overlap between the two methods.
Specific hierarchical term to parent analyses in MG-
thymoma
Each term represented by the array transcripts was compared to
its direct parent terms in the GO tree, as well as to its tree root
(MF/BP), using both continuous and discrete data analyses, as well
as tests for location and dispersion (Table S3). Several key
categories were found to be changed. These included RNA binding,
which changed (Figure S6) compared to two parent terms (MF):
transcriptional repressor activity (decreased, P = 0.01 in the continuous
method, with changed dispersion and location, P,0.05) and
compared to complement receptor activity (with a change in dispersion,
P,0.01). Cell cycle terms showed both decreases and increases
compared to its direct parent, cellular physiological process (P,0.005,
BP). More GO categories changed compared to their direct parent
terms (i.e specific analysis) than compared to the whole array
population (i.e global analysis), identifying specific GO levels that
changed and pointing at specific disease-related genes.
Finding disease-relevant genes in MG-thymoma by
combining term to parent analysis with threshold on
core exons
We used the results of our specific term analysis to search for
core exons with a cutoff threshold of 4–6 fold difference between
patients to healthy subjects. We identified 20 genes belonging to
the tumor-related, immune function and muscle-specific categories
(Table 1). To these we added ACHE, which expresses at low levels
but is highly relevant to MG [38,39]. Figure 2 presents these
changes as color-coded clusters highlighting the alternative splicing
modifications. The MF and BP categories to which the genes
belong and corresponding term-to-parent changes are listed under
Table 2 and 3. COL11A1 (Figure 3), extracellular matrix structural
constituent, changed compared to its two direct parents (Figure S6).
COL11A1 was up regulated in MG-thymoma (4–6 fold in a large
number of core probe-sets) and more moderately in colon cancer
compared to healthy colon (Figure 3A–J J and Text S3). Its first
Figure 1. Exon array analysis workflow-gene-level signals are
calculated from normalized exon array CEL files by summariz-
ing probe sets signals (either by PLIER or any other gene level
summary method). MySQL database stores exon array annotation
files and expression data at both the exon (probe-set) and gene levels.
Gene-level data, UniGene codes, as well as GO (www.geneontology.org)
ontology files and EASE [24] serve to perform functional analysis. The
functional analysis detects both globally changed GO BP and MF terms
using continuous (KS) and discrete (Fisher exact) tests, as well as specific
changes of terms compared to their parent terms. The specific
functional analysis results are used to target specific genes that
exhibited alternative splicing events or general differential expression
by presenting fold change on core probe sets of detected categories.
doi:10.1371/journal.pone.0002392.g001
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known exon was expressed in the colon but not the thymus,
whereas in MG-thymoma an extended probe set located just
before the first exon was highly expressed (Figure 3K), indicating
alternative splicing in this large (0.2 Mb) gene. Another collagen,
COL1A1 (skeletal development, BP), is notably involved in chronic
inflammation [40]. COL1A1 was up-regulated in MG-thymoma
compared to healthy thymuses and in colon cancer compared to
healthy colons. The tumor-related genes included the tyrosine
kinase receptor ERBB4 (cell proliferation, nucleotide binding, MF) which
was up-regulated in MG-thymoma (Text S3) and is de-regulated in
many human tumors [41]. In contrast, the growth factor
dermatopontin (DPT), which belongs to cell adhesion and protein
binding, was down-regulated in both cancer types (Figure 4A).
Connective tissue growth factor (CTGF) was up-regulated in
MG-thymoma compared to control thymus, control colon and
colon cancer samples (Figure 4B). The low expression levels of its
second exon in MG-thymomas may indicate exon skipping.
CTGF belongs to 4 modified MF GO categories: protein binding,
DNA replication, cell motility and epidermis development. Also in protein
binding as well as in cell adhesion and transmission of nerve impulse
(decreased, BP) is CNTNAP2, which exhibited over 4-fold increase
in 4 core probe-sets. CNTNAP2 was highly up-regulated in MG-
thymoma, exhibited low expression in colon compared to thymus,
and was down–regulated in colon cancer (Text S3). Its 39 exons
are expressed only in MG-thymoma and not in healthy thymus,
suggesting an alternative terminus. LPHN3 (also known as LEC3),
encodes a receptor activity member of the latrophilin G-protein
coupled receptors (GPCR). LEC3 was up-regulated in MG-
thymoma, but down-regulated in colon cancer (Text S3), Similar
to Adenylate cyclase (ADCY2, magnesium ion binding), and the
iroquise homeobox gene IRX2, (transcription factor activity). In
proteolysis, we identified the subtilisin PCSK2, with 4-6 fold increases
in 8 of its core probe-sets in MG-thymoma and increases in colon
cancer (Text S3), and the endopeptidases PHEX and ADAMTS20
(proteolysis), both up-regulated in MG-thymoma but not in colon
cancer (Text S3). In the BP category immune response we found the
histocompatibility MHC-II complex gene HLA-DRB1 (Figure 4C).
Its expression is significantly higher in thymus compared to colon,
with a putative 59 end-modified HLA-DRB1-002 transcript in
MG-thymoma [42]. Interleukin (IL) 19 expressed higher in thymus
than colon (Text S3) and increased in MG-thymoma. Also,
SEMA3D (cell differentiation) was highly up regulated in MG-
thymoma but not colon cancer (Text S3). The solute carrier
SLC7A10 (changed transport, BP), an inflammatory and apoptosis
modulator [43], increased both in MG-thymoma and in colon
cancer, with higher thymus than colon expression (Text S3).
The tRNA synthetase, EPRS, expressed higher in thymus than
in colon, belongs to 5 specifically changed MF GO categories:
binding, ATP binding, ligase activity, glutamyl-tRNA aminoacylation and
protein complex assembly. It was up-regulated in both MG-thymoma
and colon cancer, as well as in different cancer types [44]. Also in
ATP binding, the fibroblast growth factor receptor FGFR4 showed
over 4-fold decrease in two core probe-sets in MG-thymoma (Text
S3). FGFR4 also belongs to protein serine/threonine kinase activity and
receptor activity. The cytochrome P450 CYP4X1 gene (monooxygenase
activity, electron transport) increased in MG-thymoma compared to
healthy thymuses, with higher thymus than colon expression and
increases in colon cancer as well (Text S3).
The muscle-specific myosin MYH14 (nucleotide binding, motor
activity, MF) exhibited higher expression levels in the thymus than
other examined tissues (Text S3). It exhibited alternative splicing
in MG-thymoma tumors compared to healthy thymuses but not
between colon cancers to normal colons (Text S3). The initial
exons showed higher levels in MG-thymoma where its middle-end
exons were higher in normal thymus. This suggests the existence of
alternative variants of MHY14 in MG-thymoma compared to
normal thymuses. In addition, we observed a prominent median
gene-level increase in MG-thymoma compared to normal
thymuses (Text S3). We also detected an increase of Myosin in
MG-thymoma using Immunohistochemistry validation with
antibody specific to Myosin (Figure 5A). Indeed, MG patients
produce antibodies against structural muscle proteins, among
Figure 2. MG-thymoma targeted genes identified as subject to major changes in MG-thymoma tumors by specific, term-to-parent,
ad-hoc combined statistical analyses and ACHE. The color scale (right) presents fold changes (log base 2), and each core exonic probe set is
presented as a single band. The strand of each gene is denoted (as+for forward or-for reverse). The exons are ordered from 59 to 39 for genes on
the+strand and from 39 to 59 for genes on the-strand, such as ACHE. Note that most transcripts show mixed patterns of changes (both increases and
decreases), reflecting alternative splicing.
doi:10.1371/journal.pone.0002392.g002
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Figure 3. Detailed expression map of COL11A1 in MG-thymoma and colon cancer. The known transcript variant of COL11A1 (adopted
from ENSEMBL [7]) is shown. Additional ENSEMBL EST-based transcripts [6] of COL11A1 are shown below it. The gene was up-regulated in MG-
thymoma compared to both healthy thymus, colon cancer and healthy colon (A-J). An evidence for alternative start site in the thymus is apparent (K).
doi:10.1371/journal.pone.0002392.g003
Tumor Specific Exon Signatures
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them myosin [45] and Myosin previously showed a change
immuno-histochemistry [46].
Decreased SC35 and ASF/SF2 in MG-thymoma
Alternative splicing is modulated by the serine-arginine (SR)-
rich protein SC35 [47,48] (also known as SFRS2, splicing factor,
arginine/serine-rich 2, ENSG00000161547), which interacts with
different proteins, including ASF/SF2 (SFSR1,
ENSG00000136450) [49]. FISH and Immunohistochemistry
exhibited SC35 and ASF/SF2 decreases in the MG-thymoma
tissues (Figure 5A and Figure S7), compatible with the findings of
others [50]. Intriguingly, at the exon expression level ASF/SF2 is
higher in both healthy thymus and MG-thymoma, than in all
other examined tissues [51]. SC35 is also higher in thymus than in
all other examined tissues. However, both SC35 and ASF/SF2 are
down-regulated in inflamed muscle [52], and both showed down-
regulation in MG-thymoma (Figures 5B, C and Text S3).
Moreover, two SC35 exons show higher expression than the 39
UTR domain, suggesting alternative splicing.
A new putative ubiquitously expressed exon in the ACHE
gene
FISH for AChE-R protein variant indicated a significant
increase in the number of stained cells in the MG-thymomic
section compared to healthy thymus (Figure 5A). The largest
constitutive exon of number 2 of ACHE (Figure 6A,C) showed
pronounced expression compared to the other ACHE exons in
exon array data sets from cerebellum, breast, liver, muscle, kidney,
heart, pancreas and both normal and tumor colons (Figure 6A,
gene structure under 6B). The mRNA levels of the constitutive
exon 2 in the thymus, and yet more so in MG-thymoma tumors
were higher than in all other examined tissues (Figure 6A–C) with
mean signal intensity of 528.5 in MG-thymoma and 386.5 in
healthy thymuses compared to mean signal intensity of 158.9 in
colon cancer and 223.6 in healthy colon and 261.3 in healthy
pancreas, the highest expression compared to all the other normal
tissues. We found changes in two different categories to which
ACHE belongs: response to wounding (BP) decreased according to the
discrete approach compared to both response to external stimulus and
detection of bacteria and compared to response to external stimulus (Table
S3). Muscle contraction (BP) globally increased according to both the
discrete approach (P= 0.02) and to the KS test (P = 0.01),
compatible with our recent report [38]. Specifically, it changed
compared to its direct parent terms: organismal physiological process,
taxis (increased according to the continuous approach with a
change in location, and decreased according to the discrete
approach) and establishment of localization (increases and decreased
according to the discrete approach).
In-depth analysis of the expression levels of all ACHE probe-sets
(core, extended and full) in MG-thymoma yielded two potentially
new exons. These ACHE exons also appeared in exon array data sets
from colon cancer and multiple healthy tissues [10,20]. One of the
predicted ACHE exons (located in the intron between the
constitutive exon 3 and the alternative exon 4) showed values close
to those of the constitutive exon 2 (Figure 6A and 6C). Real-time
and quantitative RT-PCR analyses of this exon confirmed
Table 1. Targeted MG-thymoma genes
Gene name Ensamble ID Transcript cluster ID Full Gene name
ADAMTS20 ENSG00000173157 3451558 ADAM metallopeptidase with thrombospondin type 1 motif, 20
ADCY2 ENSG00000078295 2800711 Adenylate cyclase 2
CNTNAP2 ENSG00000174469 3029900 Contactin associated protein-like 2
COL1A1 ENSG00000108821 3762198 Collagen, type I, alpha 1
COL11A1 ENSG00000060718 2425756 Collagen alpha-1(XI) chain precursor
CTGF ENSG00000118523 2974330 Connective tissue growth factor
CYP4X1 ENSG00000186377 2334986 Cytochrome P450, family 4, subfamily X, polypeptide 1
DPT ENSG00000143196 2443120 Dermatopontin
EPRS ENSG00000136628 2456746 Glutamyl-prolyl-tRNA synthetase
ERBB4 ENSG00000178568 2597552 V-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)
FGFR4 ENSG00000160867 2842911 Fibroblast growth factor receptor 4
HLA-DRB1 ENSG00000196126 4048265 Major histocompatibility complex, class II, DR beta 1
IL19 ENSG00000142224 2376988 Interleukin 19
IRX2 ENSG00000170561 2846522 Iroquois homeobox protein 2
LPHN3 ENSG00000150471 2728938 Latrophilin 3
MYH14 ENSG00000105357 3839206 Myosin, heavy polypeptide 14
PCSK2 ENSG00000125851 3877892 Proprotein convertase subtilisin/kexin type 2
PHEX ENSG00000102174 3971451 Phosphate regulating endopeptidase homolog, X-linked
(hypophosphatemia, vitamin D resistant rickets)
SEMA3D ENSG00000153993 3059667 Sema domain, immunoglobulin domain (Ig), short basic domain,
secreted, (semaphorin) 3D
SLC7A10 ENSG00000130876 3858907 Solute carrier family 7, (neutral amino acid transporter, y+ system)
member 10
ACHE ENSG00000087085 3064361 Acetylcholinesterase
Detailed core probe sets expression graphs are under S12.
doi:10.1371/journal.pone.0002392.t001
Tumor Specific Exon Signatures
PLoS ONE | www.plosone.org 6 June 2008 | Volume 3 | Issue 6 | e2392
expression (Figure 6D), and sequencing of the amplified intronic
region validated its identity (Figure 6E and 6F). Repeat Masker [53]
demonstrated multiple ALu repeats in the intron where this exon
lies (intron 2–3, Text S4), suggesting ALu exonization [54], which
may lead to a prematurely terminated or smaller ACHE product.
Linking MG-thymoma exon array expression changes
with proteomic analysis
The number of proteins expressed in mammalian tissues far
exceeds that of the corresponding transcripts, likely due to
alternative splicing [7], which expands the proteome by several
orders of magnitude [55]. To link exon array data to protein
products, we used MS of proteins from tested tissues, followed by
functional annotation of the detected categories. The procedure is
described under supplementary material[56]. Peptide sequencing
obtained from 1D gel analysis of MG-thymoma and control
thymuses (DataSet S1) yielded 91 proteins showing MG-
thymoma-associated changes. These were divided into four groups
using K-Means implementation according to fold changes
between MG-thymoma and controls. Of these, about half
demonstrated peptide sequences potentially belonging to more
than one isoform, corroborating the exon array indications for
alternative splicing. These included annexin A2, fibrinogen,
chaperonin, heat shock protein, lamin A/C and DEAD box
polypeptide 17, to name a few (Figure 7A and B).
Using the number of detected peptides as protein signals, we
compared protein changes in the exon array and MS data. Many
of the detected proteins shared MF and BP GO terms identified in
our arrays (for example, both enolase and nucleolin share the
muscle development category), and overlapping changes were
observed in binding (Figure 7A). Thus, valosin-containing protein
(VCP, marked as Valosin in Figure 7) increased, both in the MS
and according to the exon array analysis (Figure 7B). VCP
contributes to ATP-dependent cellular processes and is required
for the survival of breast cancer cells [57]. The ezrin, radixin and
moesin proteins, involved in intracellular anchoring of cell
membrane proteins to the cytoskeleton [58], were detected by
both the MG-thymoma MS samples and the exon arrays
(Figure 7B). MG-thymoma radixin median exonic change
increased but ezrin and moesin decreased, reflecting specific
regulation for each member of this protein family. Inversely,
fibrinogen was only observed in control samples, perhaps
indicating its de-stabilization in the tumors.
Taken together, the RT-PCR, FISH and MS validation tests
were all supportive of the exon array findings of massive changes
in alternative splicing, in spite of the inherent limitations in each of
these methods (e.g. the requirement for tissue preservation,
variable primer efficiencies and limited resolution power of
peptide sequencing).
Discussion
We combined exon Arrays with ad-hoc and post-hoc statistics, in-
depth analysis of key modified transcripts and multi-leveled
validation tests to identify a hyper-alternative splicing signature
Table 2. MF Specific changed GO terms compared to their parent GO terms in MG-thymoma
Molecular Function (GO ID) (N) Parent (GO ID) (N) C D KW VAR
Transcription corepressor activity (3714) (16) Transcription cofactor activity (3712) (30) q !
RNA binding (3723) (83) Transcriptional repressor activity (16564) (101) Q ! !
Motor activity (3774) (17) Complement receptor activity (4875) (19) Q !
Defense/immunity protein activity (3793) (9) Complement receptor activity (4875) (11) Q ! !
Cytokine activity (5125) (33) Protein binding (5515) (378) q q !
Ion channel activity (5216) (39) Alpha-type channel activity (15268) (48) Q !
Apoptosis regulator activity (16329) (29) Molecular function q
Receptor activity (4872) (179) Signal transducer activity (4871) (377) q
Ligase activity (16874) (68) Catalytic activity (3824) (615) q
Transcriptional repressor activity (16564) (18) Transcription regulator activity (30528) (147) q q !
Extracellular matrix structural constituent ( 5201) (27) Structural molecule activity (5198) (79) !
Extracellular matrix structural constituent ( 5201) (27) Growth factor activity (8083) (47) !
Nucleotide binding ( 166) (199) Binding (5488) (968) Q Q !
Magnesium ion binding (287) (21) Molecular function q
Magnesium ion binding (287) (21) Metal ion binding (46872) (177) q Q
Transcription factor activity (3700) (78) Transcription regulator activity (30528) (135) q !
Transcription factor activity (3700) (78) Complement receptor activity (4875) (80) !
Protein binding (5515) (378) Binding (5488) (968) qQ
Protein binding (5515) (378) Metal ion binding (46872) (508) Q
DNA replication (6260) (15) DNA metabolism (6259) (50) !
Binding (5488) (968) Molecular function Q
ATP binding (5524) (176) Metal ion binding (46872) (348) qQ
monooxygenase activity (4497) (21) oxidoreductase activity (16491 ) (109) q q
Protein serine/threonine kinase activity (4674) (52) Protein kinase activity (4672) (68) Q
Full results of term-to parent analysis are under Table S3.
doi:10.1371/journal.pone.0002392.t002
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for MG-thymomas. Our findings highlighted hyper-splicing in
tumor-related, immune function and muscle-specific transcripts
with distinct patterns from those of colon cancer or healthy thymus
and included parent-child relationships in the GO hierarchy
[59,60], which specifically highlighted biologically significant
categories and transcripts. Comparison to other available micro-
array analysis techniques [61] demonstrated higher detection rate
and greater accuracy of our approach. Importantly, ASF/SF2 and
SC35, previously shown as proto-oncogens [62] exhibited highest
mRNA expression levels in the thymus then other tissues yet
decreased in MG-thymoma compared to healthy thymus at both
the protein and mRNA levels. Changes in the expression of these
proteins can affect the alternative splicing of an undefined number
of cellular transcripts and might account for some of the known
splicing changes in cancer [63–65]. Our findings thus suggest
aberrant tissue- and cancer-specific decline in alternative splicing,
accompanied by alternative hyper-splicing. Specific changes
related to MG-thymoma included HLA-DRB1, associated with a
haplotype predictive of MG susceptibility in female [66] with
specific gene variants. Up until now, the association between MG-
thymoma to MHC haplotypes spanned a thymoma-associated
class II allele on the DQB1 haplotype [67]. Also, B7, B8 (in early
MG [68,69]), DR3 (in early MG [67]), DR1, protective in MG
[67] and the DR2 allele [15] all showed associations to MG. Our
findings are hence indicative of alternative HLA-DRB transcript(s)
as being involved.
We found general increases in muscle-related GO terms and
increased myosin levels (both mRNA and protein). The mRNA
increase was significant both in MYH14 and in MYH10. A possible
splice shift observed in MYH14 gene, as compared to decrease of it
mRNA in colon cancer. Indeed, antibodies against structural
muscle proteins, among them myosin, were detected by others in
the sera of MG patients [45], and myosin mutations are associated
with colon cancer [70,71].
For cancer to metastasize from a primary tumor, the
extracellular matrix-physiological barrier whose primary structural
constituent is collagen-must be degraded to allow the passage of
tumor cells. Collagen is further involved in the immune response
to metastasis [72]. In the collagen COL1A1 gene, we detected up-
regulation in both MG-thymoma and colon cancer. Another
collagen important for cartilage collagen formation and for
organization of the extracellular matrix [73], COL11A1, was up-
regulated in MG-thymoma, perhaps reflecting a compensation
mechanism(s) over the degradation of its protein product. The
diverse expression levels of core exon probe sets in COL11A1
between colon cancer and MG-thymoma tumors may unveil
many unknown smaller transcripts, relevant to different types of
cancer. Currently, most of cancer research is conducted using
Table 3. BP Specific changed GO terms compared to their parent GO terms in MG-thymoma
Biological Process (GO ID) (N) Parent (GO ID) (N) C D KW VAR
M phase of mitotic cell cycle (87) (12 ) M phase (279) (15) !
Mitotic cell cycle (278) (13 ) Carboxylic acid metabolism (19752) (19) !
Muscle contraction (6936) (22 ) Taxis (42330) (29) q Q !
Inflammatory response (6954) (27 ) Response to wounding (9611) (45) Q ! !
Inflammatory response (6954) (27 ) Response to pest\, pathogen or parasite (9613) (36) Q !
Immune response (6955) (184 ) Response to pest\, pathogen or parasite (9613) (36) Q !
Humoral immune response (6959) (28) Response to pest\, pathogen or parasite (9613) (36) Q !
Cellular defense response (6968) (7 ) Response to pest\, pathogen or parasite (9613) (36) Q !
Response to DNA damage stimulus (6974) (10) Response to pest\, pathogen or parasite (9613) (36) Q !
Cell adhesion (7155) (80 ) Biological process Q !
tRNA metabolism (6399) (40 ) RNA metabolism (16070) (63) Q q ! !
Response to wounding (9611) (20 ) Response to external stimulus (9605) (141) Q
Glutamyl-tRNA aminoacylation (6424) (4) tRNA aminoacylation for protein translation (6418 ) (37) !
Protein complex assembly (6461) (23) Biological process q !
Morphogenesis (9653) (35) Development (7275 ) (199) q
Proteolysis (6508) (63) Biological process q
Skeletal development (1501) (15) Organ development (48513) (36) q !
Cell proliferation (8283) (43) Cellular physiological process (50875) (380) qQ !
Cell proliferation (8283) (43) Regulation of signal transduction (9966) (52) q q
Cell motility (6928) (18) Biological proces Q
Cell motility (6928) (18) Cellular physiological process (50875) (369) Q
Epidermis development (8544) (14) Biological process q !
Cell differentiation (30154) (20) Development (7275) (199) q
Cell differentiation (30154) (20) Cellular process (9987) (1163) q
Electron transport (6118) (67) Transport (6810) (317) q
Transmission of nerve impulse (19226) (23) Transport (6810) (317) q
Full results of term-to parent analysis are under Table S3.
doi:10.1371/journal.pone.0002392.t003
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standard 39 arrays, which are limited in their discovery scope. Our
study highlights potential benefits from using high-resolution
arrays in the study of cancer. Importantly, type I collagen reduces
DPT mRNA levels [74], and DPT was down-regulated both in
MG-thymoma and in colon cancer, suggesting inter-relationship
between the observed changes.
Other MG-thyoma increased transcripts included the latrophi-
lin LPHN3, which may function in both cell adhesion and signal
transduction, processes that are both essential in tumorigenesis
[75]. Also, IRX2, involved in the regulation of developmental
processes via the WNT pathway and which is notably amplified in
soft tissue sarcomas [76] was overexpressed. CNTNAP2, an
exceptionally large gene which encompasses almost 1.5% of
chromosome 7, and which functions in the vertebrate nervous
system as both a cell adhesion and a receptor molecule [77] was
increased as well. In most of these genes, we observed MG
thymoma-associated alternative hyper-splicing events (Figure 2).
We selected the low-level expressed ACHE gene for challenging
the resolution power of the Exon array technology. In both MG-
thymoma and control thymuses, we detected both the predictable
39 alternative splicing and a previously unknown exon between
introns 3 and 4, validated using RT-PCR, real-time RT-PCR and
sequencing on MG-thymoma samples. In-depth analysis of
Affymetrix exon array data sets suggests ubiquitous expression of
this novel exon, which likely originated by ALu exonization (AF8
and [54]). Further studies will be required for exploring the
biological significance of this finding, for example under stress
conditions or in neurodegenerative disease, where ACHE gene
expression is altered [7,78]. For example, inclusion of this exon
may cause early terminated translation, yielding a shorter
polypeptide with yet unknown stability and biochemical features.
Parallel not yet known ALu -derived exons likely exist in numerous
other genes[30], which calls for further exon array studies to
establish the scope of this phenomenon at the post-transcriptional
level.
MS and peptide sequencing of the MG-thymoma samples
analyzed by exon arrays, followed by clustering of identified
proteins enabled linking these data to median core gene-level
changes and corresponding GO terms. Overall, the MS results
were compatible with a complex pattern of regulation for specific
exons, genes and protein products. Median core exonic changes
thus corresponded well with tissue detection of relevant mRNAs
and proteins, even for relatively rare products such as AChE-R.
The MS approach enables simultaneous targeting of numerous
proteins, but with limited resolution compared to that of exon
expression arrays. Only major proteins are detectable, and these
Figure 4. Detailed expression map of HLA-DRB1, CTGF and DPT in MG-thymoma and colon cancer. (A) DPT is down regulated in both
MG-thymoma and colon cancer compared to healthy thymus and colon samples. (B) CTGF is up-regulated only in MG-thymoma. (C) HLA-DRB1 is up-
regulated in the thymus compared to colon tissues. It exhibits the existence of at least two transcript variants predicted by ENSEMBL [6], one that
includes exons 1 and 2 and the other, two additional exons.
doi:10.1371/journal.pone.0002392.g004
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Figure 5. mRNA and protein expression of splicing factors ASF/SF2 and SC35, Myosin and ACHE. Immunohistochemistry indicated (A)
Decrease in the mean density of the splicing factors: SR protein ASF/SF2 between MG-thymoma (i) to healthy thymus (ii) (p = 0.065) and SC35
between MG-thymoma (iii) to healthy thymus (iv) (p = 0.0001). The number of myosin expressing cells increased (p = 0.016) in MG-thymoma (v)
compared to healthy thymuses (vi). (C) FISH for AChE-R variant indicated a significant increase in the number of stained cells in the MG-thymomic
section (vii) compared to healthy thymus (viii) (p = 0.0002). (B) Exonic expression maps of ASF/SF2. All the core exons are shown. MG-thymoma (light
blue) exhibited a decrease compared to healthy thymus (dark blue) in both ASF/SF2 (B) and SC35 (C). The expression level in both healthy and cancer
thymus were higher then in other tested tissues for both (B and C). The known transcript variant of ASF/SF2 is expressed (C). SC35 exhibits expression
of two transcript variants in MG-thymoma compared to thymus samples: one containing exons 1 and 2 alone, and one containing an additional 39
exon.
doi:10.1371/journal.pone.0002392.g005
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Figure 6. ACHE gene structure, alternative transcripts and protein products, and the discovery of a Novel ACHE exon. (A) Signal
expression of ACHE exon array probe-sets in healthy pancreas, liver, muscle, kidney, heart, cerebellum and breast, colon cancer and healthy colon of
Affymetrix exon array sample data sets, aligned to known isoforms annotations. Probe set number 7 (that lies within intron 3–4) and probe set
number 16 (which is within constitutive exon 2) exhibit relatively high expression. (B) Chromosomal location of ACHE on the reverse strand of
chromosome 7 q22. The different ACHE variants (R,S,E,E’) are displayed in separate rows (data from [78]). Exon array probe sets (red) aligned to
various variant annotation and prediction sources as given in the IGB tool are shown. RefSeq known annotations (as for Exon array genome version,
2003) are shown below them, in green and blue. (C) MG-thymoma expression of ACHE exon array probe sets. Intronic probe set number 12 and
probe set 16 exhibits a clearly high expression in MG-thymoma. The signal intensity ACHE expression in MG-thymoma is significantly higher then in
all other tissues, including colon cancer, (see (A) above). Real time (i) and RT-PCR (ii) expression of the novel exon between introns 3 and 4, on both
MG-thymoma and healthy thymus samples. (E) Sequencing results of the RT-PCR product for the probe set between exons 3 and 4. (F) The sequence
identified matches a portion of the target region, and contain AG-CT splice sites.
doi:10.1371/journal.pone.0002392.g006
Tumor Specific Exon Signatures
PLoS ONE | www.plosone.org 11 June 2008 | Volume 3 | Issue 6 | e2392
Figure 7. Proteomic Analysis Combined with Exon Array Data Indicates Possible Alternative Splicing and Overlaps with Changed
GO Categories. Functional MF (circles) and BP (rectangles) GO term networks of selected changed proteins. The relative shape size (i.e circles and
rectangles) indicates the number of connected proteins. Note the complex connections between proteins sharing common GO categories. Some of
these categories changed according to the continuous exon array analysis as well. Comparison between protein and gene levels for proteins
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randomly break into peptides and may be falsely identified by the
upper layer alignment software because only one or two peptides
can be observed. Notably, MS-detected proteins sharing the same
GO categories showed interactions with exon-array analysis
results, suggesting networks relating to the examined disease.
Additionally, proteins sharing one biological process are more
likely to interact than proteins involved in distinct processes [79].
Also, dis-similarities between mRNA and protein changes may
indicate measurement errors, post-translational events, distinct
turn-over rates or alternative splicing. In contrast, FISH and
immunohistochemistry are highly sensitive, albeit limited in scale,
thus enabling identification of subtle yet specific mRNA and
protein changes.
Combining exons, whole transcripts and functional analyses
with protein data and available exon array data sets can add
further support to exon array studies. In view of the complexity of
alternative splicing processes, our finding of a clear hyper-splicing
signature for MG-thymoma suggests physiological significance for
this signature. This, in turn, supports a notion whereby such exon-
array derived signatures can serve for diagnosis as well as for
rational drug design. The information provided by exon array
experiments thus expands our biological knowledge on known and
new transcript variants, opening new potential avenues for
research, diagnosis and therapeutics.
Materials and Methods
Human thymus tissue samples
Freshly discarded thymic fragments were obtained from
immunologically healthy female and male patients undergoing
corrective cardiovascular surgery or from MG patients undergoing
prophylactic thymectomy at the Centre Chirurgical Marie
Lannelongue (Le Plessis Robinson, France). All MG patients
included in the study were treated with anticholinesterases but not
with corticosteroids or immunosuppressors. Thymoma tissues
were removed for therapeutic purpose and fragments of normal
thymus tissues were removed to make the large vessels more
accessible during cardiac surgery. Pathologists at the Centre
Chirurgical Marie Lannelongue (Le Plessis Robinson, Paris,
France) determined the classification of thymoma. The Institu-
tional Review Board: Comite´ de Protection des Personnes de
Kremlin-Biceˆtre approved the use of human tissues based on
verbal consents alone. Our IRB explained that written informed
consents were not mandatory, since the tissues were initially
harvested for therapeutic purposes and because all donors
remained anonymous. Samples are described under Table S4.
RNA isolation
RNA was extracted from frozen thymus samples using the
RNeasy lipid tissue kit (Qiagen, Valencia, CA) as per manufac-
turer’s instructions from healthy and pathological thymus samples.
DNase treatment was applied to avoid DNA contamination. RNA
integrity was confirmed by gel electrophoresis, and RNA
concentration and purity were assessed spectrophotometrically.
Human exon 1.0 ST microarray experiment
1 mg of total RNA from MG-thymoma (male, 44 and female,
53), control (male, 43 and female, 46) thymuses was labeled with
the Affymetrix exon array whole transcripts sense targeting
labeling assay and reagents, including r-RNA reduction and
labeling with Streptavidin-phycoerithrin. Each sample was
hybridized to a GeneChipH Exon 1.0 ST Array (Affymetrix,
Santa Clara, CA, USA) according to manufacturer’s instructions,
and results scanned to create four .CEL files using Affymetrix GCS
3000 7G scanner and GeneChip Operating Software v. 1.3 to
produce .CEL intensity files.
Additional exon array data files and normalization
Human colon cancer and all other available tissues sample data
sets of Affymetrix exon array in .CEL files were downloaded from
Affymetrix web site (http://www.affymetrix.com/support/techni-
cal/sample_data/exon_array_data.affx).
The data was normalized using Affymetrix ExACT software to
sketch normalize exon array data. Probes of all the probe sets
(core, extended and full) were summarized using ExACT [80].
Gene-level iter-plier results are given under ST1. Each exon array
probe-set is annotated in one of three possible levels: core,
extended and full, according to the annotation source of the
interrogated region. Core probe sets are supported by most
reliable information, associated with full-length coding sequence
mRNA evidence from RefSeq and GenBank records. Extended
transcript clusters are based on cDNA evidence and include other
human mRNA and EST sequences, ENSEMBL gene collections,
synthetically mapped mRNAs from mouse and rat, mitoMap
mitochondrial genes, microRNA registry genes, vegaGene and
vegaPseudoGene records. Full Transcript Clusters are supported
by gene and exon prediction algorithms including GeneID [81],
GenScan [82], GenScanSubOpt [83], exoniphy [84], RNAGene
[85], sgpGene [86] and Twinscan [87]. Each probe set contains
several probes (typically 4) [10].
Statistical data analysis and bioinformatics
Functional GO analysis.
Mapping of transcript clusters to UniGene identifiers
Transcript cluster IDs were assigned to their corresponding
UniGene clusters using transcript_annot file [80]. For each
transcript, all the UniGenes that are included in its region were
considered for further functional analysis.
Mapping of UniGene identifiers to corresponding GO terms
EASE [24] program served to identify all of the BP and MF GO
terms that are represented on the human 1.0 ST Exon array. GO
ontology files (www.geneontology.org) enabled defining of all the
UniGenes (UG) associated with each represented GO term.
Statistical tests found increases or decreases in expression using the
discrete Fisher exact test with a 2-fold threshold, and continuous
KS statistics, analyzing each tail separately.
Colon cancer exon array data set [20] functional analysis
20 samples of colon cancer and healthy colons [20] (N= 10 in
each) were analyzed. For gene level analysis, we used iter-PLIER
[80] gene level transcript signals of the colon cancer data set
published by Affymetrix [20]. We calculated the mean log ratio,
and coefficient variation (CV) score for each group (data available
upon request). UniGene identifiers and their corresponding signals
were analyzed using continuous and discrete GO analysis using
KS and Fisher exact test, respectively.
detected as changed using 1D MS analysis. Ninety-one changed proteins were detected using K-means clustering on the peptide signals information
(supplementary methods). Relative signals for selected proteins were calculated from the mean number of peptides detected in MG-thymoma and
healthy Thymus samples, and compared to the median exonic expression level of the corresponding genes as detected by the exon arrays. In some,
both decreased, in some both increased and in the rest, opposite changes occurred.
doi:10.1371/journal.pone.0002392.g007
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Colon cancer arrays comparison using GO analyses
From colon cancer exon array data [20], changed genes
(N= 159) obtained from Affymetrix quantile sketch normalization
and ANOVA p-values and fold changes[20]. We applied EASE
[24] to obtain enriched BP GO categories.
Enriched BP GO categories in the list of changed genes in colon
cancer, using microarray analyses, obtained from Bush and
coworkers [35], where ErmineJ [33] was used to analyze GO of
1975 differentially expressed probesets identified by the empirical
Bayes HotellingT2 model [35]. GO analyses of protein maps
obtained by 2D gel MS analysis of colon cancers were obtained
from Patel and coworkers [37]. A list of changed BP GO
categories using functional analysis of colon cancer using
microarrays was obtained from Maglietta and coworkers [36].
Full results table will be given upon request.
MG-thymoma exon array data set functional analysis
UG identifier lists were extracted and then GO [88] annotations
of these lists were obtained by EASE [24]. To obtain gene level
signals, the median core exonic fold change of each UG cluster
was calculated. UG identifiers and their corresponding signals
were grouped into their corresponding GO terms, and analyzed
using continuous and discrete GO analysis using KS and Fisher
exact test, respectively, as compared with the global array
population. Additionally, global term-to-parents analysis was
conducted on the whole group of array-represented GO terms,
to compare each term to each of its direct parent terms, and to its
GO tree root (i.e MF/BP). This specific analysis was conducted
using KS, Fisher exact, Kruskal-Wallis and variance tests.
MG-thymoma exon array permutated data set
To perform permutations, the median fold changes of the
thymus samples were mixed twice. Then, log2 ratio between the
mixed datasets was calculated. Continuous and discrete analyses
were performed on the MG-thymoma permutated data (results
under Supplementary Material). KS, variances and Kruskal-Wallis
tests also served to examine specific changes in GO categories
compared to their direct and indirect parent GO terms.
Database construction
A MySQL database was constructed and used to store exon
array expression signals at the exon probe-set level, as well as
annotation data from the analyzed samples, in corresponding
tables, for efficient transcript-specific queries.
Other applications
An upper layer Java program was used to access specific
transcripts information. To examine global exonic and gene-level
signals at different gene fragments, a Visual Basic application was
written. Matlab 7.1.0.246–R14 [89] used to perform all statistical
analyses.
Immunohistochemistry
Polyclonal antibodies for SC35, Myosin (Sigma, St. Louis, MI)
and AS/SF2 (Zymed, San Francisco, CA) were used at 1:100,
1:100, 1:20 dilutions, respectively. Sections were deparaffinized,
permeabilized and incubated with 100 mM Glycine in PBS for
20 min at room temp, preblocked with buffer containing 5%
donkey serum, 0.5% Tween20 in PBS (1 h, at room temp) and
incubated with primary antibodies (overnight, at 4uC). Biotiny-
lated antibodies were incubated with Cy3-conjugated streptavidin
(Jackson ImmunoResearch Laboratories, West Grove PA, USA).
Sections were coverslipped and analyzed by confocal microscopy
using a Bio-Rad MRC-1024 scanhead (Hemel Hempsted,
Hertfordshire, U.K.) equipped with a digital camera and Olympus
FV-1000 confocal microscopes, using excitation and emission
parameters suitable for Cy3. Four areas (54 m2) were photo-
graphed from each section with SC35 and ASF/SF2 labeling and
the mean density per area was quantified with the software
package ImagePro4 (Media Cybernetics, Silver Spring, MD).
Myosin immunohistochemistry was performed on 106m2 sections
and the same software was used to analyze the number of stained
cells per area. Student’s t-test was used to determine the statistical
significance between healthy and MG-thymoma sections.
Fluorescence In Situ Hybridization (FISH)
Deparaffinization and rehydration of the tissue, permeabiliza-
tion by proteinase K and prehybridization were as detailed
elsewhere [39]. Following prehybridization for 30 min, at 60uC
with hybridization buffer (50% formamide, 750 mmol/L sodium
chloride, 75 mmol/L sodium citrate at pH 4.5, 50 mg/mL
heparin and 50 mg/mL tRNA), hybridization was performed for
(2h, 52uC) with 1 mg/mL 59-biotinylated, 2-O-methylated ACHE
cRNA probe complementary to human AChE-R mRNA (Micro-
synth GMBH (Balgach, Switzerland)). Microscopy and data
analysis involved four 106m2 areas from each section and stained
cell numbers per area were determined.
Real-time RT-PCR
For each sample, 0.4 mg RNA was used for 20 ml cDNA
synthesis using Promega RT-PCR kit (Promega, Madison, WI).
Real-time RT-PCR was performed in triplicate for each sample
using ABI prism 7900HT and SYBR green master mix (Applied
Biosystems, Foster City, CA). ROX, a passive reference dye, was
used for signal normalization across the plate. Primer sequences
are described under Table S5. Annealing temperature was 60u C
for all primers. Serial dilution of samples served to evaluate
primers efficiency and the appropriate cDNA concentration that
yields linear changes. Melting curve analysis and amplicon
sequencing verified the end product and b-actin served as
reference gene.
* Additional Materials and methods are under Text S5.
Supporting Information
Figure S1 The number of GO categories presenting discrete
and continuous changes in MG-thymoma by Venn diagrams. BP
and MF categories that presented discrete (denoted as D) 2-fold
change (dark gray) or continuous (denoted as C) change of median
transcript exonic expression level using KS statistics (light gray)
and both methods (intersection areas) as compared with the total
population of UniGene clusters represented on the array. Note
that in both MF and BP, more categories decreased than
increased, and more categories showed change in the continuous
approach than the discrete.
Found at: doi:10.1371/journal.pone.0002392.s001 (0.14 MB TIF)
Figure S2 Tumor-specific Gene and Exon Level Expression
Changes. Exon level probe sets showed a decrease fold change
trend in MG-thymoma compared to healthy thymus (Ai). In colon
cancer, an inverse increase trend appeared compared to healthy
colon data (Aii). In both, the trend was conserved across all
annotation levels-core, extended and full (Ai and Aii). Specifically,
core level exons decreased in MG-thymoma compared to colon
tumorgenesis events (Aiii). Median gene-level global exon array
population exhibited decrease in MG-thymoma tissues compared
to healthy thymuses, corresponding to exon-level changes (Aiv).
The change was significant and differed from that of permutated
populations (Figure S3). (B) The center 80% exons of all
transcripts showed larger expression decrease than both 39 and
59 10% portions (statistical information under Supplementary
Material). (C) Focusing only at terminal probes, the 39 of MG-
thymoma samples exhibited decrease of the exons in the 39 60 bps,
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compared to the 600 bps region (low KS P-value ,0.05), with a
change in dispersion (variances test P-value = 0; exon data was
included if at least half of it was within the tested transcript
boundaries). (D) Exonic changes were slightly different between 39
to the 59 10% genomic region of all transcripts. 39 edge increased
pronouncedly with changes both in location (i) and in the number
of genes with changed exons (ii). (E) At the 5% genomic region, the
39 edge regions decreased compared to the 59, with a difference in
location and dispersion (i) and the number of changed genes (ii). (F)
The 2.5% fragment resolution revealed a striking difference in
exonic change patterns between the 39 to the 59 edges, expressed
in distributional tails, location and dispersion (i) as well as the
number of changed genes (ii).
Found at: doi:10.1371/journal.pone.0002392.s002 (1.17 MB TIF)
Figure S3 Comparison of total global median core exons change
in MG-thymoma and colon cancer. A) The median core exonic
gene level signal is shown for MG-thymoma and colon cancer, for
all the UniGene clusters represented on the array. Generally,
colon cancer (N= 10) increased compared to MG-thymoma
changes (N=4) significantly (high KS P-value = 0). MG-thymoma
and colon cancer samples were compared to matching healthy
samples accordingly, and then to one another. B) (i) Median core
exonic gene level signal, for MG-thymoma compared to healthy
thymus samples (blue), with permutated patients and healthy
samples changes (green and red). (ii) Median core exonic gene level
signal, for colon cancer compared to healthy colon samples (blue),
with permutated patients and healthy samples changes (green and
red).
Found at: doi:10.1371/journal.pone.0002392.s003 (0.63 MB TIF)
Figure S4 Comparison of median expression change in MG-
thymoma 39 60 to 600 base pairs. Median exonic change of all
array transcripts, was considerably smaller within the 39 60
nucleotides (N=2,131) then in the 39 600 bps (N= 16,318).
Statistical information under Supplementary Material.
Found at: doi:10.1371/journal.pone.0002392.s004 (0.36 MB TIF)
Figure S5 Comparison between expression differences in
various gene edges between the 39 to 59 of genes. A. MG-
thymoma compared to healthy thymus samples (i)Median Exonic
change of 39 compared to 59 10% edge fragments of all array
transcripts. There was a slight increase (CDF plot) in the 59 Exonic
change (high KS,0.05) with a change in location and dispersion.
(ii) Median Exonic change of 39 compared to 59 5% edge
fragments of all array transcripts. There was a slight decrease
(CDF plot) in the 59 Exonic change (high KS,0.05) with a change
in location and dispersion. (iii) Median Exonic change of 39
compared to 59 2.5% edge fragments of all array transcripts. A
striking difference between edges is observed, at both distributional
tails (high and low KS P-values = 0), and both dispersion and
location. (iv) In the 59 edge, no change between median exonic
changes observed between 10%, 5% and 2.5% of all the
transcripts. B. Colon cancer compared to healthy colon samples
Median Exonic change of 39 compared to 59 2.5% edge frag-
ments of all array transcripts. There was a decrease (CDF plot, low
KS P-value = 0.05) in the 59 Exonic change compared to the 39
edge.
Found at: doi:10.1371/journal.pone.0002392.s005 (0.56 MB TIF)
Figure S6 Specific GO category change compared to its parent
terms. The change in RNA binding (N= 83) category compared to
both direct and indirect GO parents. The blue and red bars
indicate UniGenes that decrease and increased more then 2-fold,
accordingly. (i) RNA binding decreased (low KS P-value ,0.05)
compared to the global parent term, MF (N=21,047). (ii) RNA
binding decreased (low KS P-value ,0.05) also compared to its
direct parent term, nucleic acid binding (N= 280).
Found at: doi:10.1371/journal.pone.0002392.s006 (0.60 MB TIF)
Figure S7 Median core exons change of ASF/SF2, SC35,
Myosins and AChE-R. The median core exonic log fold change as
compared between MG-thymoma to healthy thymus samples, for
the validated genes. Myosin (MYH10), lymphocyte-specific
myosin (MYLC2PL) and AChE-R increased, whereas SC-35
and ASF/SF2 decreased.
Found at: doi:10.1371/journal.pone.0002392.s007 (0.05 MB TIF)
Text S1 Functional Analysis of Colon Cancer Data Set Exhibits
Large Overlaps with Other Colon Cancer Data Sets. Results of
comparisons between our continuous and discrete ad-hoc
functional GO statistical analysis to other ad- and post- hoc
functional GO analyses on colon cancer microarray and
proteomic data sets.
Found at: doi:10.1371/journal.pone.0002392.s008 (0.10 MB
DOC)
Text S2 Global Exons Probe Sets Changes in Different Gene
Portions of MG-Thymoma and Colon Cancer. Statistical results of
the comparisons between different gene edges (39 and 59 regions)
expression changes between MG-thymoma to healthy thymuses,
and differs from permutated MG-thymoma data set.
Found at: doi:10.1371/journal.pone.0002392.s009 (0.03 MB
DOC)
Text S4 The Intron in which the New ACHE Exon is Located is
Enriched with ALu Repeats. Results of repeat masker [53] on the
constitutive ACHE exons number 2 and 3, intron 2–3 and intron
3–4 (where the new exon is located).
Found at: doi:10.1371/journal.pone.0002392.s010 (0.04 MB
DOC)
Text S3 Core Probe Sets Normalized Signals Intensity of
Detected MG-Thymoma genes. Expression signals intensity of
core probe sets of the MG-thymoma genes detected by the specific
term to parent ad-hoc approach combined with fold change
threshold are given for MG-thymoma and healthy thymuses.
Found at: doi:10.1371/journal.pone.0002392.s011 (0.09 MB
DOC)
Text S5 Additional materials and methods
Found at: doi:10.1371/journal.pone.0002392.s012 (0.04 MB
DOC)
DataSet S1 1D-Gel Mass Spectrometry Proteomic Analysis
Results on the MG-Thymoma and Healthy Thymus Samples. All
the identified peptides are given, with the corresponding proteins
identified by clustering analysis and NCBI database [4]
Found at: doi:10.1371/journal.pone.0002392.s013 (1.72 MB
XLS)
Table S1 Ad-hoc Global Functional BP and MF GO Analysis of
Exon Array Colon Cancer Data. Results of Affymetrix exon array
colon cancer data set [20] are given for MF and BP. The columns
of the Excel table are as indicated: the name of GO term, its GO
ID, p-values of the continuous method (KS-P high tail test), testing
the hypothesis that the tested distribution contains larger values
than the global distribution, of Fisher exact test (Fishex INC, the
high tail test) using the hypergeometric distriution (i.e, the discrete
method), testing the hypothesis that the tested distribution contains
larger than expected number of increased (INC) genes (using a 2-
fold cutoff), the KS-P (low tail) testing the hypothesis that the
distribution contains smaller values than those observed with the
global distribution and Fishex (DEC) for testing the hypothesis that
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the testes distribution contain larger than expected number of
decreased (DEC) genes (using a 2-fold cutoff). N is The number of
transcripts associated with the GO term, KS accur (KS accuracy)
is a number indicating the reliability of the KS test. The p-value is
most accurate when KS accur .4. Additionaly, the percent of
transcripts changed above the threshold is given for each category
(named % changed genes), and the number of genes changed
more then the threshold (named #changed genes). The red and
blue cells in the tables indicate the GO terms that significantly
increased or decreased, respectively (at significance level of p-value
,0.05).
Found at: doi:10.1371/journal.pone.0002392.s014 (0.62 MB
XLS)
Table S2 Ad-hoc Global Functional BP and MF GO Analysis of
Exon Array MG-Thymoma Data Set. Results of Affymetrix exon
array MG-thymoma data set are given for BP and MF. The
columns of the Excel table are as follows: Name (GO term title)
,GO ID, KS-P (high), Fishex (INC),KS-P (low),Fishex (DEC), KS-
P (high), percent changed genes and number of changed genes.
The red and blue cells in the tables indicate the GO terms that
significantly increased or decreased, respectively (p,0.05). De-
tailed description of each column is given under S1 description.
Found at: doi:10.1371/journal.pone.0002392.s015 (0.37 MB
XLS)
Table S3 Specific, Term-To-Parent Functional GO Analysis
Results on MG-Thymoma Data Set. Results of hierarchical
comparison between GO terms to their direct and indirect (BP/
MF) parent GO terms in MG-thymoma exon array data set are
given for all the terms represented on Affymetrix exon 1.0 S_T
array. The columns of the Excel table are: Name (of GO term),
GO ID (of the term), Parent name (the name and GO ID of the
compared parent, KS-P (high): p-value for the one tailed KS test
(ie, the continuous method), testing the hypothesis that the tested
distribution contains larger values than the global distribution,
Fishex (INC): p-value for the Fisher exact test using the
hypergeometric distribution (ie, the discrete method), testing the
hypothesis that the tested distribution contains a larger than
expected number of increased (INC) genes (using a 2-fold cutoff),
KS-P (low)-a p-value for the one tailed KS test (ie, the continuous
method), testing the hypothesis that the tested distribution contains
smaller values than those observed with the global distribution,
Fishex (DEC): a p-value for the Fisher exact test using the
hypergeometric distribution (ie, the discrete methods), testing the
hypothesis that the testes distribution contain larger than expected
number of decreased (DEC) genes (using a 2-fold cutoff), N-the
number of transcripts associated with the GO term, KS accur (KS
accuracy)-a number indicating the reliability of the KS test. The p-
value is most accurate when KS accur .4.VAR: P value for
variances (VAR) test indicating a change in dispersion and of
Kruskal Wallis (KW) test indicate a change in location. The
percent of transcripts that changed more than the threshold (both
increased and decreased) of all the GO term transcripts (% change
genes), the number of changed genes (# changed genes)-the
number of transcripts that changed more than the threshold (both
increased and decreased) out of all the GO term transcripts. The
red and blue cells in the tables indicate the GO terms that
significantly increased or decreased, respectively, at significance
level of 0.05.
Found at: doi:10.1371/journal.pone.0002392.s016 (5.76 MB
XLS)
Table S4 Samples Description of MG-Thymoma and Healthy
Thymus. Detailed description of the MG-thymoma and healthy
thymus data set.
Found at: doi:10.1371/journal.pone.0002392.s017 (0.03 MB
XLS)
Table S5 PCR Primers for ACHE New Exon. PCR primers
design obtained from Primer3 software (www.frodo.wi.mit.edu/)
and were used for both gel electrophoration of RT-PCR and for
Real-Time RT-PCR.
Found at: doi:10.1371/journal.pone.0002392.s018 (0.03 MB
XLS)
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